in-Pharma Technologist.com reports that Bayer Healthcare has decided to invest in a new center for biotechnology production to support generation of "innovative" pharmaceuticals. This would be a complement to Bayer's small molecule holdings.
The new plant is to be built in Wuppertal, Germany at a projected cost of $47 M. Bayer says its main focus lies with the manufacture of antibodies, as well as coagulation factors and other therapeutic proteins, and the firm hopes the new center will increase its chances of being able to offer new drugs in the fight against serious diseases such as cancer. Operations at the 1000sq meter facility are expected to begin at the end of 2012.
Posted by Bruce Lehr December 16th 2010.